Evaluating the efficiency of specimen pooling for PCR-based detection of COVID-19.
COVID-19
/ diagnosis
COVID-19 Testing
/ economics
Disease Notification
/ economics
Epidemiological Monitoring
Humans
Limit of Detection
Nasopharynx
/ virology
Pandemics
Pharynx
/ virology
Prevalence
RNA, Viral
/ genetics
Real-Time Polymerase Chain Reaction
/ economics
Retrospective Studies
SARS-CoV-2
/ genetics
Specimen Handling
/ economics
Thailand
/ epidemiology
Viral Load
COVID-19
PCR
SARS-CoV-2
cost efficiency
real-time PCR
specimen pooling
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
01
05
2020
revised:
10
05
2020
accepted:
11
05
2020
pubmed:
14
5
2020
medline:
30
12
2020
entrez:
14
5
2020
Statut:
ppublish
Résumé
In the age of a pandemic, such as the ongoing one caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the world faces a limited supply of tests, personal protective equipment, and factories and supply chains are struggling to meet the growing demands. This study aimed to evaluate the efficacy of specimen pooling for testing of SARS-CoV-2 virus, to determine whether costs and resource savings could be achieved without impacting the sensitivity of the testing. Ten previously tested nasopharyngeal and throat swab specimens by real-time polymerase chain reaction (PCR), were pooled for testing, containing either one or two known positive specimens of varying viral concentrations. Specimen pooling did not affect the sensitivity of detecting SARS-CoV-2 when the PCR cycle threshold (Ct) of original specimen was lower than 35. In specimens with low viral load (Ct > 35), 2 of 15 pools (13.3%) were false negative. Pooling specimens to test for Coronavirus Disease 2019 infection in low prevalence (≤1%) areas or in low risk populations can dramatically decrease the resource burden on laboratory operations by up to 80%. This paves the way for large-scale population screening, allowing for assured policy decisions by governmental bodies to ease lockdown restrictions in areas with a low incidence of infection, or with lower-risk populations.
Identifiants
pubmed: 32401343
doi: 10.1002/jmv.26005
pmc: PMC7272832
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2193-2199Subventions
Organisme : King Chulalongkorn Memorial Hospital's Excellent Center Program
ID : EC-63-30101-29
Pays : International
Organisme : National Research Council of Thailand
Pays : International
Organisme : Biological Threat Reduction Program of the US Defense Threat Reduction Agency
ID : HDTRA 1-17-C-0004
Pays : International
Informations de copyright
© 2020 The Authors. Journal of Medical Virology Published by Wiley Periodicals LLC.
Références
J Med Virol. 2020 Oct;92(10):2193-2199
pubmed: 32401343
N Engl J Med. 2005 Aug 11;353(6):631-3; author reply 631-3
pubmed: 16093476
JAMA. 2020 May 19;323(19):1967-1969
pubmed: 32250394
Am J Clin Pathol. 2020 May 5;153(6):715-718
pubmed: 32304208
N Engl J Med. 2005 May 5;352(18):1873-83
pubmed: 15872202
N Engl J Med. 2004 Aug 19;351(8):760-8
pubmed: 15317889
Science. 2020 Mar 20;367(6484):1287-1288
pubmed: 32193299
BMJ. 2020 Mar 18;368:m1090
pubmed: 32188598
N Engl J Med. 2020 May 21;382(21):2049-2055
pubmed: 32202722
J Med Virol. 2020 Nov;92(11):2306-2307
pubmed: 32369202
J Clin Invest. 2004 Apr;113(7):937-45
pubmed: 15057296
J Clin Microbiol. 1990 Mar;28(3):495-503
pubmed: 1691208